PEA方案与5-Fu+KSM方案治疗妊娠滋养细胞肿瘤疗效比较

doi:10.7504/fk2014080121

摘要/Abstract

摘要：

目的探讨PEA方案是否可以作为妊娠滋养细胞肿瘤联合化疗一线选择。方法回顾性分析中国医科大学附属盛京医院2004年7月至2013年5月62例妊娠滋养细胞肿瘤患者，评价顺铂+足叶乙甙+更生霉素（PEA方案,30例）与氟尿嘧啶+更生霉素（5-Fu+KSM，32例）方案的疗效和毒副反应。结果 PEA方案治疗妊娠滋养细胞肿瘤完全缓解率为93.33%，高于5-Fu+KSM方案组（90.63%）（P>0.05）。副反应PEA组Ⅲ～Ⅳ度粒细胞减少、口腔溃疡和腹泻情况明显少于5-Fu+KSM组，差异有统计学意义（P<0.05）。PEA组恶心呕吐和肝功能损伤的发生率及严重程度均低于5-Fu+KSM组（P>0.05）。结论两方案治疗妊娠滋养细胞肿瘤疗效相当，PEA方案副反应小、疗程短、费用少，可以作为妊娠滋养细胞肿瘤联合化疗一线选择之一。

关键词: 妊娠滋养细胞肿瘤, 顺铂, 足叶乙甙, 更生霉素, 氟尿嘧啶

Abstract:

Abstract： Objective To explore whether the PEA regimen can be used as the first-line chemotherapy drug for gestational trophoblastic neoplasms.Methods Retrospectively analyze 62 cases of gestational trophoblastic neoplasms from July 2004 to May 2013 in our hospital. Compare the treatment efficacy and side effects of these two regimens.Results The effective rate of PEA regimen for the treatment of gestational trophoblastic neoplasms was 93.33%,higher than that of 5-Fu+KSM regimen,but it has no significant difference (P>0.05). In the aspect of the side effects, III～IV leukopenia, oral cavity ulcer and diarrhea of PEA group were less than those of 5-Fu + KSM group,being of significant difference (P<0.05). In the aspect of nausea , vomiting and liver function damage, the occurrence rate in PEA group was lower than that in 5-Fu + KSM group,but it was of no significant difference (P>0.05).Conclusion Two regimens have the same effect, but PEA regimen has fewer side effects, shorter duration of average hospital stay and less treatment cost,which can be used as first-line chemotherapy drug for gestational trophoblastic neoplasms.

Key words: gestational trophoblastic neoplasms, DDP;VP16;KSM;5-Fu

中图分类号:

R737.3

马晓琳，王欣彦，李秀琴. PEA方案与5-Fu+KSM方案治疗妊娠滋养细胞肿瘤疗效比较[J]. 中国实用妇科与产科杂志, DOI: 10.7504/fk2014080121.

MA Xiao-lin，WANG Xin-yan，LI Xiu-qin. The clinical comparison of effects of PEA regimen and 5-Fu+KSM regimen for treatment of gestational trophoblastic neoplasms.[J]. Acta Metallurgica Sinica, DOI: 10.7504/fk2014080121.

参考文献

［1］    Li MC, Hertz R, Spencer DB. Effects of methotrexate therapy upon choriocarcinoma and chorioadenoma［J］.Proc Soc Exp Biol Med,1956,93(2):361-366.

［2］    Kohorn EI.The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment［J］.Int J Gynecol Cancer，2001,11 (1):73-77.

［3］    Ngan HY.The practicability of FIGO 2000 staging for gestational trophoblastic neoplasia ［J］. Int J Gynecol Cancer,2004,14(2):202-205.

［4］    曹泽毅．中华妇产科学［M］．2版．北京：人民卫生出版社，2004：2215-2216．

［5］    孙燕，周际昌．临床肿瘤内科手册［M］．4版．北京：人民卫生出版社，2003：321-323.

［6］    Alazzam M, Tidy J, Hancock BW, et al . First-line chemotherapy in low-risk gestational trophoblastic neoplasia［J］.Cochrane Database Syst Rev，2012,11(7):CD007102.

［7］ Cavoretto P,Gentile C,Mangili G,et al. Transvaginal ultrasound predicts delayed response to chemotherapy and drug resistance in stage I low-risk trophoblastic neoplasia［J］.Ultrasound Obstet Gynecol，2012,40(1):99-105.

［8］   Chapman-Davis E, Hoekstra AV, Rademaker AW, et al .Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia:factors associated with resistance to single-agent methotrexate chemotherapy［J］.Gynecol Oncol ,2012 ,125(3):572-575.

［9］    杨焯，钱建华. 低危型妊娠滋养细胞肿瘤耐药高危因素探讨［J］. 中国实用妇科与产科杂志,2011,27（7）:526-529.

［10］    Lurain JR,Nejad B.Secondary chemotherapy for high-risk gestational trophoblastic neoplasia ［J］. Gynecol Oncol,2005,97(2):618-623.

（2014-05-02收稿    2014-06-24修回）

[1]	程红燕, 向阳. 妊娠滋养细胞肿瘤的免疫治疗[J]. 中国实用妇科与产科杂志, 2022, 38(7): 693-696.
[2]	李克敏, 尹如铁. 高危妊娠滋养细胞肿瘤的治疗[J]. 中国实用妇科与产科杂志, 2022, 38(7): 691-693.
[3]	刘晓梅, 李秀琴. 低危妊娠滋养细胞肿瘤的治疗[J]. 中国实用妇科与产科杂志, 2022, 38(7): 687-691.
[4]	彭美莲, 林开武, 翁宗杰, 吴齐斌, 孙蓬明. 妊娠滋养细胞疾病的影像学特征及意义[J]. 中国实用妇科与产科杂志, 2022, 38(7): 680-684.
[5]	吕卫国, 陈丽莉. 重视妊娠滋养细胞肿瘤的规范化治疗[J]. 中国实用妇科与产科杂志, 2022, 38(7): 673-675.
[6]	王芬芬, 鲍可纯, 程晓东. 特殊病理类型妊娠滋养细胞肿瘤的治疗[J]. 中国实用妇科与产科杂志, 2022, 38(7): 696-701.
[7]	奚玲, 孙玥. 妊娠滋养细胞肿瘤生育力保留策略[J]. 中国实用妇科与产科杂志, 2022, 38(7): 701-704.
[8]	苏昊, 冯凤芝. 难治性滋养细胞肿瘤的治疗[J]. 中国实用妇科与产科杂志, 2022, 38(5): 511-514.
[9]	王丽娟, 林海雪, 林仲秋. 《2022 NCCN妊娠滋养细胞肿瘤临床实践指南（第1版）》解读[J]. 中国实用妇科与产科杂志, 2022, 38(1): 78-84.
[10]	王丽娟，林海雪，林仲秋. 《2021 NCCN妊娠滋养细胞肿瘤临床实践指南（第2版）》解读[J]. 中国实用妇科与产科杂志, 2021, 37(5): 564-569.
[11]	王丽娟，林海雪. 《2020年RCOG妊娠滋养细胞疾病管理指南》解读[J]. 中国实用妇科与产科杂志, 2021, 37(2): 198-204.
[12]	贺桂芳，凌斌. 子宫颈癌术前辅助治疗的规范化[J]. 中国实用妇科与产科杂志, 2021, 37(1): 44-48.
[13]	向阳，蒋芳. 妊娠滋养细胞肿瘤药物治疗研究进展[J]. 中国实用妇科与产科杂志, 2020, 36(1): 25-28.
[14]	杜江悦，吕卫国. 上皮样滋养细胞肿瘤的诊治[J]. 中国实用妇科与产科杂志, 2017, 33(4): 350-353.
[15]	吕卫国. 复发性耐药性妊娠滋养细胞肿瘤的诊治[J]. 中国实用妇科与产科杂志, 2015, 31(3): 220-223.